Market research
1S7.F Selecta Biosciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 8.67
- Dividend yield
- Not available
- Beta
- 0.83
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8162121045
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 8.67
- Dividend yield
- Not available
- Beta
- 0.83
About
About Selecta Biosciences, Inc
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1S7.F discussion.
5 years, 5 months ago
Selecta Biosciences, Inc is currently in a long term uptrend where the price is trading 5.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 26.7.
Selecta Biosciences, Inc's total revenue rose by 79.6% to $12M since the same quarter in the previous year.
Its net income has dropped by 3.7% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.4% to $-7M since the same quarter in the previous year.
Based on the above factors, Selecta Biosciences, Inc gets an overall score of 4/5.